Liquidia Announces Poster Presentation and Medical Theater at the CHEST 2024 Annual Meeting
Liquidia (NASDAQ: LQDA) announced its participation in the CHEST 2024 annual meeting hosted by the American College of Chest Physicians on October 6-9, 2024, in Boston. The company will present a poster and host a medical theater at the event. The poster, titled "Baseline Characteristics of Patients Enrolled in the ASCENT Study: Evaluating Safety and Tolerability of YUTREPIA™, A Dry Powder Inhaled Treprostinil in Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)," will be presented on October 9th. It will focus on Liquidia's ongoing clinical trial, dosing and tolerability profiles, and exploratory efficacy endpoints for YUTREPIA in PH-ILD patients.
The medical theater, scheduled for October 7th, will discuss current epidemiologic data on PH-ILD, the clinical data gap regarding dry-powder treprostinil use in PH-ILD, and how Liquidia's ASCENT study is addressing this gap, as well as the future of PH-ILD treatments.
Liquidia (NASDAQ: LQDA) ha annunciato la sua partecipazione al CHEST 2024 annual meeting organizzato dal American College of Chest Physicians dal 6 al 9 ottobre 2024 a Boston. L'azienda presenterà un poster e ospiterà un teatro medico durante l'evento. Il poster, intitolato "Caratteristiche di Base dei Pazienti Arruolati nello Studio ASCENT: Valutazione della Sicurezza e Tollerabilità di YUTREPIA™, un Treprostinil Inalato in Polvere Secca nella Ipertensione Polmonare Associata a Malattia Polmonare Interstiziale (PH-ILD)," sarà presentato il 9 ottobre. Si concentrerà sullo studio clinico in corso di Liquidia, i profili di dosaggio e tollerabilità, e gli endpoint di efficacia esplorativa per YUTREPIA nei pazienti con PH-ILD.
Il teatro medico, programmato per il 7 ottobre, discuterà i dati epidemiologici attuali sulla PH-ILD, il divario nei dati clinici riguardo all'uso di treprostinil in polvere secca nella PH-ILD, e come lo studio ASCENT di Liquidia stia affrontando questo divario, oltre al futuro dei trattamenti per la PH-ILD.
Liquidia (NASDAQ: LQDA) anunció su participación en la reunión anual CHEST 2024 organizada por el American College of Chest Physicians del 6 al 9 de octubre de 2024 en Boston. La empresa presentará un póster y organizará un teatro médico en el evento. El póster, titulado "Características Basales de los Pacientes Inscritos en el Estudio ASCENT: Evaluando la Seguridad y Tolerabilidad de YUTREPIA™, un Treprostinil Inhalado en Polvo Seca en Hipertensión Pulmonar Asociada con Enfermedad Pulmonar Intersticial (PH-ILD)," será presentado el 9 de octubre. Se centrará en el ensayo clínico en curso de Liquidia, los perfiles de dosificación y tolerabilidad, y los puntos finales de eficacia exploratoria para YUTREPIA en pacientes con PH-ILD.
El teatro médico, programado para el 7 de octubre, discutirá los datos epidemiológicos actuales sobre la PH-ILD, la brecha de datos clínicos sobre el uso de treprostinil en polvo seco en la PH-ILD, y cómo el estudio ASCENT de Liquidia está abordando esta brecha, así como el futuro de los tratamientos para la PH-ILD.
Liquidia (NASDAQ: LQDA)는 2024년 10월 6일부터 9일까지 보스턴에서 개최되는 CHEST 2024 연례 회의에 참여할 것이라고 발표했습니다. 회사는 이 행사에서 포스터를 발표하고 의료 극장을 주최할 예정입니다. "ASCENT 연구에 등록된 환자의 기초 특성: 간질성 폐 질환(PH-ILD)과 관련된 폐 고혈압에서 YUTREPIA™, 건조 분말 흡입형 트레프로스틴일의 안전성 및 내약성 평가"라는 제목의 포스터는 10월 9일에 발표될 예정입니다. 이 포스터는 Liquidia의 진행 중인 임상 시험, 용량 및 내약성 프로필, 그리고 PH-ILD 환자에 대한 YUTREPIA의 탐색적 효능 지표에 중점을 둘 것입니다.
10월 7일에 예정된 의료 극장에서는 PH-ILD에 대한 현재의 역학 데이터, PH-ILD에서 건조 분말 트레프로스틴일 사용에 관한 임상 데이터 공백, 그리고 Liquidia의 ASCENT 연구가 이 공백을 어떻게 해소하고 있는지, 또한 PH-ILD 치료의 미래에 대해 논의할 것입니다.
Liquidia (NASDAQ: LQDA) a annoncé sa participation à la réunion annuelle CHEST 2024 organisée par l'American College of Chest Physicians du 6 au 9 octobre 2024 à Boston. L'entreprise présentera un poster et accueillera un théâtre médical lors de l'événement. Le poster, intitulé "Caractéristiques de Base des Patients Inscrits dans l'Étude ASCENT : Évaluation de la Sécurité et de la Tolerabilité de YUTREPIA™, un Treprostinil Inhalé en Poudre Sèche dans l'Hypertension Pulmonaire Associée à une Maladie Pulmonaire Interstitielle (PH-ILD)," sera présenté le 9 octobre. Il se concentrera sur l'essai clinique en cours de Liquidia, les profils de dosage et de tolérance, ainsi que les points d'efficacité exploratoires pour YUTREPIA chez les patients atteints de PH-ILD.
Le théâtre médical, prévu pour le 7 octobre, discutera des données épidémiologiques actuelles sur la PH-ILD, de la lacune des données cliniques concernant l'utilisation du treprostinil en poudre sèche dans la PH-ILD, et comment l'étude ASCENT de Liquidia aborde cette lacune, ainsi que l'avenir des traitements pour la PH-ILD.
Liquidia (NASDAQ: LQDA) gab bekannt, dass es an der CHEST 2024-Jahrestagung teilnehmen wird, die vom American College of Chest Physicians vom 6. bis 9. Oktober 2024 in Boston ausgerichtet wird. Das Unternehmen wird während der Veranstaltung ein Poster präsentieren und ein medizinisches Theater veranstalten. Das Poster mit dem Titel "Basismerkmale von Patienten, die in die ASCENT-Studie eingeschlossen sind: Bewertung der Sicherheit und Verträglichkeit von YUTREPIA™, einem trockenen Pulverinhalator mit Treprostinil bei pulmonaler Hypertonie, die mit interstitieller Lungenerkrankung (PH-ILD) assoziiert ist," wird am 9. Oktober vorgestellt. Es wird sich auf die laufende klinische Studie von Liquidia, Dosierungs- und Verträglichkeitsprofile sowie explorative Wirksamkeitsendpunkte für YUTREPIA bei PH-ILD-Patienten konzentrieren.
Das medizinische Theater, das für den 7. Oktober geplant ist, wird aktuelle epidemiologische Daten zu PH-ILD, die Datenlücke in Bezug auf die Anwendung von trockenem Treprostinil bei PH-ILD und die Art und Weise, wie die ASCENT-Studie von Liquidia diese Lücke angeht, sowie die Zukunft der PH-ILD-Behandlungen erörtern.
- Liquidia is presenting research on its YUTREPIA product at a major medical conference
- The company is conducting the ASCENT clinical trial for YUTREPIA in PH-ILD patients
- Liquidia is addressing a clinical data gap in dry-powder treprostinil use for PH-ILD
- None.
MORRISVILLE, N.C., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases, announced today the company will present a poster and host a medical theater at the CHEST 2024 annual meeting hosted by the American College of Chest Physicians on October 6-9, 2024, in Boston.
Rajeev Saggar, MD, Chief Medical Officer at Liquidia, said: “Every year, CHEST unites the next generation of medical professionals and organizations responsible for advancing patient care and educating the future leaders in our field. As such, we are proud to be sharing insight regarding our ongoing ASCENT trial evaluating the safety and tolerability of YUTREPIA™ (treprostinil) inhalation powder in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD).”
Liquidia’s poster, entitled “Baseline Characteristics of Patients Enrolled in the ASCENT Study: Evaluating Safety and Tolerability of YUTREPIA™, A Dry Powder Inhaled Treprostinil in Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD),” will be presented on Wednesday, October 9th, 2024, from 10:20 a.m. – 11:05 a.m. ET. The poster will focus on the company’s ongoing clinical trial, dosing and tolerability profiles, and exploratory efficacy endpoints for the use of YUTREPIA in PH-ILD patients in the ASCENT trial.
Upon presentation, the poster will be available on Liquidia’s website at https://liquidia.com/products-and-pipeline/publications.
The company’s medical theater, which will take place on October 7, 2024 from 12:15 p.m. to 1:00 p.m. ET and is open to all meeting attendees, will focus on current epidemiologic data on PH-ILD, the clinical data gap regarding dry-powder treprostinil use in PH-ILD and how Liquidia’s ASCENT study is addressing this gap, as well as the future of PH-ILD treatments.
About YUTREPIA™ (treprostinil) Inhalation Powder
YUTREPIA is an investigational, inhaled dry-powder formulation of treprostinil delivered through a convenient, low-effort, palm-sized device. The FDA previously issued tentative approval of YUTREPIA for the PAH indication in November 2021. In July 2023, Liquidia filed an amendment to its New Drug Application for YUTREPIA, seeking to add PH-ILD to the label. YUTREPIA was designed using Liquidia’s PRINT® technology, which enables the development of drug particles that are precise and uniform in size, shape and composition, and that are engineered for enhanced deposition in the lung following oral inhalation. Liquidia has completed INSPIRE, or Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil, an open-label, multi-center phase 3 clinical study of YUTREPIA in patients diagnosed with PAH who are naïve to inhaled treprostinil or who are transitioning from Tyvaso® (nebulized treprostinil). YUTREPIA is currently being studied in the ASCENT trial, an Open-Label Prospective Multicenter Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in Pulmonary Hypertension, with the objective of informing YUTREPIA’s dosing and tolerability profile in patients with PH-ILD. YUTREPIA was previously referred to as LIQ861 in investigational studies.
About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease. The company’s current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT® Technology. PRINT enabled the creation of Liquidia’s lead candidate, YUTREPIA™ (treprostinil) inhalation powder, an investigational drug for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company is also developing L606, an investigational sustained-release formulation of treprostinil administered twice-daily with a next-generation nebulizer, and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit www.liquidia.com.
Tyvaso® is a registered trademark of United Therapeutics Corporation.
Cautionary Statements Regarding Forward-Looking Statements
This press release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts, including statements regarding our future results of operations and financial position, our strategic and financial initiatives, our business strategy and plans and our objectives for future operations, are forward-looking statements. Such forward-looking statements, including statements regarding clinical trials, clinical studies and other clinical work (including the funding therefor, anticipated patient enrollment, safety data, study data, trial outcomes, timing or associated costs), regulatory applications and related submission contents and timelines, and our ability to execute on our strategic or financial initiatives, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives and financial needs. These forward-looking statements are subject to a number of risks discussed in our filings with the SEC, as well as a number of uncertainties and assumptions. Moreover, we operate in a very competitive and rapidly changing environment and our industry has inherent risks. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the future events discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Nothing in this press release should be regarded as a representation by any person that these goals will be achieved, and we undertake no duty to update our goals or to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact Information
Investors:
Jason Adair
Chief Business Officer
919.328.4350
jason.adair@liquidia.com
Media:
Patrick Wallace
Director, Corporate Communications
919.328.4383
patrick.wallace@liquidia.com
FAQ
What is Liquidia presenting at the CHEST 2024 annual meeting?
When and where is the CHEST 2024 annual meeting taking place?
What is the focus of Liquidia's (LQDA) poster presentation at CHEST 2024?
What topics will be covered in Liquidia's (LQDA) medical theater at CHEST 2024?
